Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Wunderlich

Showing results (71-80 of 112) with videos related to

Pageof 12
Sort By:
The Journal of Clinical Investigation|December 17, 2013
Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activityChinavenmeni S Velu, Aditya Chaubey, James D Phelan, et al.
The Journal of Pathology|May 13, 2017
CD44 variant isoform 9 emerges in response to injury and contributes to the regeneration of the gastric epitheliumNina Bertaux-Skeirik, Mark Wunderlich, Emma Teal, et al.
Cell Reports|August 3, 2024
SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiationYu-Hsuan Chang, Keita Yamamoto, Takeshi Fujino, et al.
Plos One|September 3, 2010
DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemiaSara Alvarez, Javier Suela, Ana Valencia, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2010
Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemiaShuangli Mi, Zejuan Li, Ping Chen, et al.
Nature|August 5, 2011
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaJohannes Zuber, Junwei Shi, Eric Wang, et al.
The Journal of Clinical Investigation|March 10, 2020
Targeting AML-associated FLT3 mutations with a type I kinase inhibitorLaQuita M Jones, Katelyn Melgar, Lyndsey Bolanos, et al.
Nature Communications|December 2, 2025
DDX6 undergoes phase separation to modulate metabolic plasticity and chemoresistanceHongjie Bi, Wei Li, Lili Ren, et al.
Cancer Discovery|April 11, 2022
Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML BlastsJana M Ellegast, Gabriela Alexe, Amanda Hamze, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 8, 2012
MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemiaXi Jiang, Hao Huang, Zejuan Li, et al.
Pageof 12

Showing results (71-80 of 112) with videos related to

Sort By:
Pageof 12
The Journal of Clinical Investigation|December 17, 2013
Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activityChinavenmeni S Velu, Aditya Chaubey, James D Phelan, et al.
The Journal of Pathology|May 13, 2017
CD44 variant isoform 9 emerges in response to injury and contributes to the regeneration of the gastric epitheliumNina Bertaux-Skeirik, Mark Wunderlich, Emma Teal, et al.
Cell Reports|August 3, 2024
SETDB1 suppresses NK cell-mediated immunosurveillance in acute myeloid leukemia with granulo-monocytic differentiationYu-Hsuan Chang, Keita Yamamoto, Takeshi Fujino, et al.
Plos One|September 3, 2010
DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemiaSara Alvarez, Javier Suela, Ana Valencia, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 6, 2010
Aberrant overexpression and function of the miR-17-92 cluster in MLL-rearranged acute leukemiaShuangli Mi, Zejuan Li, Ping Chen, et al.
Nature|August 5, 2011
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemiaJohannes Zuber, Junwei Shi, Eric Wang, et al.
The Journal of Clinical Investigation|March 10, 2020
Targeting AML-associated FLT3 mutations with a type I kinase inhibitorLaQuita M Jones, Katelyn Melgar, Lyndsey Bolanos, et al.
Nature Communications|December 2, 2025
DDX6 undergoes phase separation to modulate metabolic plasticity and chemoresistanceHongjie Bi, Wei Li, Lili Ren, et al.
Cancer Discovery|April 11, 2022
Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML BlastsJana M Ellegast, Gabriela Alexe, Amanda Hamze, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 8, 2012
MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemiaXi Jiang, Hao Huang, Zejuan Li, et al.
Pageof 12